At VasoCollar, we transform physicians' needs into innovative, standardized solutions to address critical clinical challenges—specifically, rapid vascular anastomosis and blood flow restoration. We have proof-of-concept data for 2.5 mm and 5 mm vessels in trauma and plastic surgery and have applied for four patents in the USA, China, and Taiwan since 2020. Our initial market focus is trauma, and we have secured a contract with the U.S. Department of Defense in 2014, and collaborate with Brooke Army Medical Center and Stanford Medicine in 2025. With FDA approval expected in 2026, we will launch 20 clinical trials for market entry. We are currently raising $1.5 million in angel investment to finalize product design, scale mass production, and achieve FDA approval by the end of 2026.